Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial
The Pharma Data
JUNE 7, 2023
3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Grade 3 or greater treatment-related adverse events (TRAEs) occurred in 31% of patients receiving doublet therapy and 58% of patients receiving triplet therapy. The percentage of ILD or pneumonitis events was similar across cohorts.
Let's personalize your content